January 16, 2026 8:09am

Risks to valuations already in process, leaves the C&GT sector vulnerable to further disappointment

Some running for flights to end the hectic JPM HC week

Pre-open Signals: 2 Positive and 2 Negative; If you understand probabilities, the inevitable is easier to maneuver

Never leave retail investor uninformed … I say what others won’t, so you can do what others 

RMi Closing Bell: Day#4, JP Morgan Healthcare Conference ends as share pricing got breeched this week … https://www.regmedinvestors.com/articles/14270  

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): A new financing attempt? … https://www.regmedinvestors.com/articles/13812

RMi Research Note: Capricor Therapeutics (CAPR) DUMP before the next big SLUMP! … https://www.regmedinvestors.com/articles/14249       

 

Friday: The pre-open Dow futures are DOWN -0.02% or (- points), the S&P futures are UP +0.20% or (+13 points) and the Nasdaq futures are UP +0.52% or (+133 points)

  • U.S. stock futures are inching and mixed on Friday 1/16
  • European markets were fluctuating and mixed having opened up,
  • Asia Pacific markets rose

Economic Data: Industrial production, Capacity utilization and Home builder confidence index

                                                               

I chose to speak-up when many analysts, brokers and commentators have shut-up!

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Thursday: The Dow closed UP +292.81 points or +0.60%, the S&P closed UP +17.87 points or +0.26% while the Nasdaq closed UP +58.272 points or +0.25%
  • Wednesday: The Dow closed DOWN -42.24 points or -0.09%, the S&P closed DOWN -36.75 points or -0.53% while the Nasdaq closed DOWN -238.123 points or -1%
  • Tuesday: The Dow closed DOWN -398.21 points or -0.80%, the S&P closed DOWN -13.53 points or -0.19% while the Nasdaq closed DOWN -24.032 points or -0.10%
  • Monday: The Dow closed UP +86.13 points or +0.17%, the S&P closed UP +10.99 points or +0.16% while the Nasdaq closed UP +62,558 points or +0.26%
  • Last Friday: The Dow closed UP +237,96 points or +0.48%, the S&P closed UP +44.82 points or +0.65% while the Nasdaq closed UP +191.331 points or +0.82%
  • Last week: The S&P 500 was up +1.6%, the Dow +2.3% and the Nasdaq was up +1.9%.
  • The previous week: The S&P 500 was down -1.2%, the Dow was down -1.3% and the Nasdaq was down -1.5%.
  • December ended with the S&P 500 up +16.4%, the Dow +13% and the Nasdaq +20.4%

 

Q1/26 – Q1 – 1 holiday, 2 neutral, 3 negative and 4 positive closes  

Q4 – December,

  • 1 holiday, 8 positive and 12 negative closes
  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Beam Therapeutics (BEAM) closed down -$3.36 after Wednesday’s +$0.86, Tuesday’s +$0.86 and Monday’s +$6.14 with a positive +$0.46 or +1.44% pre-open

BioNTech (BNTX) closed down -$3.05 after Wednesday’s +$1.93, Tuesday’s +$5.01, Monday’s +$2.33 and last Friday’s +$1.00 with a positive +$2.46 or +2.32% pre-open

Vertex (VRTX) closed down -$10.61 with a negative -$1.42 or -0.32 pre-open indication

Capricor Therapeutics (CAPR) closed Thursday down -$0.75 after Wednesday’s flat, Tuesday’s +$0.28 after Monday’s +$0.67 after Friday’s closed down -$0.78 with a negative -$0.04 or -0.17% pre-open indication

  • As CAPR’s investment bank jumps into protecting its offering pricing – Don’t be SWAYED by their BUYING!!
  • I am STICKING to my CONVICTION that CAPR is overbought and whose valuation is disconnected from fundamentals.
  • Doubts still abound re: regulatory fragility and marginal HOPE-3 results and valuation concerns remain a key hang-up!
  • CAPR remains a structurally challenged, chronically unprofitable company whose valuation is disconnected from fundamentals.
  • It has begun; timing will be everything!
  • The higher CAPR rises, the steeper the fall!

 

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

In 2026, investors should focus on whether cell and gene therapy sector equities can sustain momentum through clinical execution, regulatory milestones, commercialization progress, financings and potential strategic transactions; although Q4 and FY25 earnings cycle could slow upsides

Let's NOT forger the coming LPS (loss-per-share) Q4 anf FY25 earnings season, a few had some partial "peaks" during the JP Morgan Healthcare Conference ... don't do much!

  • I hate to be so negative or contrarian but, this is a NO spin zone and facts and truth are its products; I can always be WRONG but, I am mostly EARLY!
  • if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

January – 3nd week:

  • 1/15 - Thursday closed negative with 8 incliners, 30 decliners and 2 flats
  • 1/14 – Wednesday closed positive with 27 incliners, 11 decliners and 2 flats
  • 1/13 – Tuesday closed neutral with 19 incliners, 19 decliners and 2 flats
  • 1/12 – Monday closed neutral with 19 incliners, 19 decliners and 2 flats

January – 2nd week’s session

  • 1/9 - Friday closed negative with 10 incliners, 28 decliners and 2 flats
  • 1/8 – Thursday closed negative with 7 incliners, 30 decliners and 3 flats
  • 1/7 – Wednesday closed positive with 33 incliners, 5 decliners and 2 flats
  • 1/6 – Tuesday closed positive with 27 incliners, 11 decliners and 2 flats
  • 1 /5 - Monday closed negative with 18 incliners, 21 decliners and 1 flat

First week:

  • 1 /2 - Friday closed positive with 18 incliners, 17 decliners and 5 flats
  • 1/1 -Thursday was a holiday, New Years Day

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.